Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

This study (called CONSOLIDATE) is testing enfortumab vedotin — a targeted drug that delivers chemotherapy directly to cancer cells — combined with radiation therapy in people with locally advanced bladder cancer that cannot be fully removed with surgery. **You may be eligible if...** - You are 18 or older - You have bladder cancer confirmed by biopsy (urothelial carcinoma), including T4N0 or T1–T4 with lymph node involvement (N2–N3) - Your general health is reasonably good (ECOG 0–2) - Your blood counts (hemoglobin, platelets, neutrophils) and kidney function are within acceptable limits **You may NOT be eligible if...** - You have uncontrolled diabetes or severe nerve damage in your hands/feet (peripheral neuropathy) - You have active skin conditions or significant eye problems - You are pregnant or breastfeeding - You have received certain prior treatments that would conflict with this study Talk to your doctor to see if this trial is right for you.